Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Health and Happiness (H&H) International Holdings ( (HK:1112) ) has shared an announcement.
Health and Happiness (H&H) International Holdings reported low double-digit revenue growth for 2025 on both reported and like-for-like bases, driven by gains across its adult, baby and pet nutrition segments. The company said Chinese mainland and other expansion markets delivered particularly strong performances, with innovative categories such as heart health, anti-aging, detox and premium ranges like Swisse Plus supporting mid-single-digit growth in Adult Nutrition and Care, while Australia and New Zealand domestic sales grew despite a strategic pullback from the corporate daigou channel.
The Baby Nutrition and Care segment returned to clear growth, with infant milk formula posting strong double-digit gains that significantly outpaced the broader Chinese market following a successful product standard transition and intensified outreach via social media, e-commerce and baby specialty stores. Pediatric probiotics and supplements resumed growth with new product launches and expanded channels, and Pet Nutrition and Care achieved high-single-digit like-for-like growth, led by mid-teens expansion in high-margin pet supplements, while group adjusted EBITDA is expected to rise 2–6% with margins remaining close to the mid-teens, underscoring solid profitability alongside the top-line momentum.
The most recent analyst rating on (HK:1112) stock is a Buy with a HK$18.80 price target. To see the full list of analyst forecasts on Health and Happiness (H&H) International Holdings stock, see the HK:1112 Stock Forecast page.
More about Health and Happiness (H&H) International Holdings
Health and Happiness (H&H) International Holdings is a consumer health and wellness group focused on adult, baby and pet nutrition and care products. Its portfolio spans vitamins and supplements, infant milk formula, pediatric probiotics and pet supplements, with major markets in mainland China, Australia and New Zealand and other expansion regions.
Average Trading Volume: 1,600,455
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.33B
See more insights into 1112 stock on TipRanks’ Stock Analysis page.